2+ day, 14+ hour ago   (255+ words) EAGAN, Minn., Sept. 10, 2026 /PRNewswire/ -- Prime Therapeutics LLC (Prime) today announced that Manmohan Mahajan has been appointed as the company's chief financial officer (CFO), effective immediately. Mahajan brings more than 20 years of global finance and leadership experience across healthcare, pharmacy and…...

2+ day, 22+ hour ago   (499+ words) iStock, Agdekon Media Visuals Takeda’s R&D chief Andy Plump will say good-bye to the drugmaker, with a retirement slated for next summer. “Andy has made the personal decision to retire in June 2027 after more than 10 years leading Takeda’s global…...

3+ day, 3+ hour ago   (406+ words) No more is launching a drug a “straight math exercise,” as Most Favored Nation drug pricing pressures drugmakers to reconsider launch sequences to ensure the best price can be achieved in the main global market: the United States. That’s according…...

3+ day, 3+ hour ago   (768+ words) BioSpace Community Clinical Research Joins PhaseWell Research to Anchor Inpatient CNS Capabilities and Expand Clinical Trial Access Across Austin and Broader Texas Region The partnership establishes Community Clinical Research as the foundation of PhaseWell’s inpatient neuropsychiatric research capabilities, deepening the…...

3+ day, 3+ hour ago   (423+ words) Encoded Therapeutics has closed a $275 million series F round to help advance its investigational Dravet syndrome therapy into pivotal development. Much of the proceeds will go toward Encoded’s lead asset ETX101, according to a Wednesday release. The therapy is being tested…...

3+ day, 15+ hour ago   (506+ words) For a small biotech, the more practical incentive is time. Speed matters—whether a drug succeeds or fails. Finding out earlier that the biology is wrong stops further investment, limits unnecessary exposure of patients and allows scientists and resources to…...

4+ day, 2+ hour ago   (169+ words) Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion Capstone — Pediatric Study Touchstone — Special Population Study Clinical Perspective…...

4+ day, 3+ hour ago   (512+ words) BioSpace IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as…...

4+ day, 5+ hour ago   (197+ words) Caspian Therapeutics has arrived on the biopharma scene, bringing with it $50 million in starting funds, a potentially disease-modifying answer for diabetes and the backing of the industry’s biggest player in metabolic disease, Eli Lilly. The funding push was led by…...

4+ day, 23+ hour ago   (489+ words) BioSpace Alterome Therapeutics Appoints Johanna Mylet as Chief Financial Officer Former Poseida Therapeutics CFO joins Alterome Therapeutics as the company prepares to accelerate development of KRAS-targeting medicines SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the…...